The pharmaceutical industry has long been a battleground for innovation, with companies around the globe constantly striving to outpace each other in developing cutting-edge therapies. Oncology, the branch of medicine that deals with cancer, has emerged as a focal point of this dynamic competition.
The ongoing search for better and safer treatments for multiple myeloma, a type of blood cancer, has taken a significant step forward with the development of a new cell therapy by Arcellx and Gilead Sciences. The pioneering approach demonstrated a substantial reduction or total eradication of
Naobios and Sumagen Canada Inc., a subsidiary of CreoSG Co., Ltd, have achieved a critical milestone in the development of Sumagen’s HIV-1 vaccine candidate, SAV001. This genetically modified, whole-killed HIV vaccine has shown both tolerance and safety in phase I trials, marking a significant step
GC Biopharma and Novelty Nobility have announced a promising partnership aimed at developing a novel treatment for geographic atrophy (GA), a severe form of dry age-related macular degeneration (AMD). This condition leads to retinal damage and eventual blindness, making it a significant health
Pluri Inc., a forward-thinking biotechnology firm, has recently announced a groundbreaking collaborative project with Bar-Ilan University’s Research and Development Company (BIRAD). This innovative endeavor aims to develop cutting-edge allogeneic cell therapies specifically targeting solid tumors,
Jade Biosciences, a burgeoning developer specializing in immune disease drugs, has set its sights on accelerating its market presence through a reverse merger with Aerovate Therapeutics. This strategic consolidation will enable Jade to promptly enter the public market under the Nasdaq ticker
